Life Sciences Monetization After San Diego: The UPC as Portfolio Strategy
The lesson of this year's BIO International Convention in San Diego 1 is not that the market has finally discovered the Unified Patent Court; it has been aware of it for some time.
Read the full articleYou might also wanna read
STAT+: Pharmalittle: We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and more
STAT·17h ago
STAT+: Pharmalittle: We’re reading about FDA commissioner contenders, a heart drug failure, and more
STAT·1d ago
Chronic hepatitis C diagnosed prevalent cases to reach 7.46 million across 8MM in 2035, forecasts GlobalData
globaldata.com·1d ago
Japan: IP High Court Launches Amicus Call on the Scope of PTE
Kluwer Arbitration Blog·1d ago
STAT+: RFK Jr. plans to create list of injuries caused by Covid-19 vaccines
STAT·2d ago
STAT+: White House reviewing top contenders to lead FDA
STAT·2d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.